Kalmar Investments Inc. DE cut its stake in shares of West Pharmaceutical Services Inc. (NYSE:WST) by 14.0% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 830,860 shares of the company’s stock after selling 135,333 shares during the period. West Pharmaceutical Services comprises about 2.8% of Kalmar Investments Inc. DE’s investment portfolio, making the stock its largest position. Kalmar Investments Inc. DE owned 1.14% of West Pharmaceutical Services worth $63,046,000 as of its most recent filing with the SEC.

A number of other institutional investors have also recently bought and sold shares of WST. Silvercrest Asset Management Group LLC raised its position in West Pharmaceutical Services by 1.3% in the first quarter. Silvercrest Asset Management Group LLC now owns 13,307 shares of the company’s stock valued at $922,000 after buying an additional 177 shares during the last quarter. Whittier Trust Co. raised its position in shares of West Pharmaceutical Services by 1.2% in the second quarter. Whittier Trust Co. now owns 21,649 shares of the company’s stock valued at $1,643,000 after buying an additional 262 shares in the last quarter. BlackRock Inc. raised its position in shares of West Pharmaceutical Services by 1.1% in the first quarter. BlackRock Inc. now owns 45,038 shares of the company’s stock valued at $3,122,000 after buying an additional 511 shares in the last quarter. New York State Teachers Retirement System raised its position in shares of West Pharmaceutical Services by 0.5% in the second quarter. New York State Teachers Retirement System now owns 131,270 shares of the company’s stock valued at $9,961,000 after buying an additional 600 shares in the last quarter. Finally, Teachers Advisors Inc. raised its position in shares of West Pharmaceutical Services by 0.7% in the first quarter. Teachers Advisors Inc. now owns 104,680 shares of the company’s stock valued at $7,256,000 after buying an additional 744 shares in the last quarter. Institutional investors own 90.17% of the company’s stock.

Institutional Ownership by Quarter for West Pharmaceutical Services (NYSE:WST)

Shares of West Pharmaceutical Services Inc. (NYSE:WST) traded up 0.50% during midday trading on Tuesday, hitting $72.97. 302,080 shares of the company’s stock were exchanged. The stock has a market cap of $5.34 billion, a PE ratio of 53.15 and a beta of 0.86. West Pharmaceutical Services Inc. has a 1-year low of $53.88 and a 1-year high of $84.33. The stock’s 50 day moving average is $77.62 and its 200-day moving average is $75.92.

West Pharmaceutical Services (NYSE:WST) last issued its quarterly earnings results on Thursday, July 28th. The company reported $0.59 EPS for the quarter, topping analysts’ consensus estimates of $0.56 by $0.03. The business earned $388 million during the quarter, compared to the consensus estimate of $384.58 million. West Pharmaceutical Services had a net margin of 6.99% and a return on equity of 14.40%. The company’s quarterly revenue was up 7.9% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.47 earnings per share. Analysts predict that West Pharmaceutical Services Inc. will post $2.22 earnings per share for the current fiscal year.

The business also recently announced a quarterly dividend, which will be paid on Wednesday, November 2nd. Investors of record on Wednesday, October 19th will be issued a $0.13 dividend. This represents a $0.52 dividend on an annualized basis and a yield of 0.71%. This is an increase from West Pharmaceutical Services’s previous quarterly dividend of $0.12. The ex-dividend date of this dividend is Monday, October 17th. West Pharmaceutical Services’s payout ratio is presently 35.04%.

A number of research firms have issued reports on WST. Zacks Investment Research lowered shares of West Pharmaceutical Services from a “hold” rating to a “sell” rating in a report on Wednesday, September 28th. Janney Montgomery Scott reiterated a “fair value” rating and set a $72.55 target price (down from $90.00) on shares of West Pharmaceutical Services in a report on Monday, September 26th. Wells Fargo & Co. lowered shares of West Pharmaceutical Services from an “outperform” rating to a “market perform” rating in a report on Wednesday, September 21st. Finally, Jefferies Group reissued a “hold” rating on shares of West Pharmaceutical Services in a research report on Thursday, August 4th.

In related news, Director Paula A. Johnson sold 3,042 shares of the business’s stock in a transaction that occurred on Tuesday, August 23rd. The shares were sold at an average price of $81.55, for a total value of $248,075.10. Following the completion of the sale, the director now directly owns 38,450 shares in the company, valued at $3,135,597.50. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, SVP Karen Flynn sold 14,581 shares of the business’s stock in a transaction that occurred on Tuesday, September 6th. The shares were sold at an average price of $83.28, for a total transaction of $1,214,305.68. Following the completion of the sale, the senior vice president now owns 13,513 shares of the company’s stock, valued at $1,125,362.64. The disclosure for this sale can be found here. 5.13% of the stock is currently owned by corporate insiders.

West Pharmaceutical Services Company Profile

West Pharmaceutical Services, Inc (West) is a manufacturer of components and systems for the packaging and delivery of injectable drugs, as well as delivery system components for the pharmaceutical, healthcare and consumer products industries. The Company’s segments include Pharmaceutical Packaging Systems segment (Packaging Systems) and the Pharmaceutical Delivery Systems segment (Delivery Systems).

5 Day Chart for NYSE:WST

Receive News & Stock Ratings for West Pharmaceutical Services Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for West Pharmaceutical Services Inc. and related stocks with our FREE daily email newsletter.